Spectral AI, Inc. announced the addition of seven clinical sites that are currently enroll to support the development of its diabetic foot ulcer (DFU) application for the DeepView Wound Imaging System. The proprietary technology combines multi-spectral imaging and AI technology to provide clinicians with an immediate healing assessment of DFU's for more accurate and timely diagnosis and therapeutic intervention. Participating investigators and clinical sites include: Dr. Tony Alleman, MD, University of Tennessee Health Science Center.

Dr. Ian Barron, DPM, Gentle Foot Care Hilliard and Gentle Foot Care Grove City. Dr. Stephen Frania, DPM, Foot and Ankle Specialist of Ohio Dr. Vladimir Zeetser, DPM, Premium Podiatry and Wound Care. Dr. Charles Ananian, DPM, New Hope Podiatry Group.

Dr. Karl Fulkert, DPM, Worthington Foot and Ankle indication. The data collected from these additional sites will be incorporated to bolster the database for the development of the DFU healing prediction algorithm using the Company's DeepView®? technology and support the Company's applications for FDA, UKCA, and CE mark approval for DeepView®?'s DFU indication.DFU is a severe chronic diabetic complication that consists of lesions in the deep tissues associated with neurological disorders and peripheral vascular disease in the lower limbs.

It is the most frequently recognized, complex and costly symptom of diabetes that can lead to limb amputation if left undiagnosed, misdiagnosed, or untreated. Due to U.S. reimbursement rules, physicians are currently required to wait 30 days to designate a DFU as non-healing before using advanced wound care therapies, resulting in higher probability of infections, longer healing times and significant lifetime medical costs for the patient. DeepView®?'s early healing assessment for DFU has the potential to provide a significant improvement to the current standard of care, resulting in faster application of advanced therapy when needed, better wound healing, and reduced overall hospital visits.